Lentiviral and retroviral vectors have relatively large payload capacities. They can transfect dividing and non-dividing cells for CAR-T cell therapy development which gives them potential to serve as stand-alone vectors for gene therapy.
The Center for Breakthrough Medicines offers scalable vector production for research, preclinical, clinical and commercial manufacturing clients. Cutting-edge single-use technologies support rapid process development efforts with access to extensive testing and product characterization expertise and capabilities via next-generation analytical methods.
Co-located process development, testing, characterization, and commercialization support services help ensure successful delivery of clinical and commercial material for our clients.